pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›dotinurad
drug
save

dotinurad

Phase 3updated 3mo ago
by Crystalys Therapeutics Inc
Phase 3
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying dotinurad

  • phase3A Study of Dotinurad Versus Allopurinol in Participants With Goutrecruitingn=500
  • phase3A Study of Dotinurad Versus Allopurinol in Tophaceous Goutrecruitingn=250
  • phase2A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participantsnot yet recruitingn=90
  • phase3A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Goutcompletedn=451
  • phase2Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemiacompletedn=20
  • phase1A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participantscompletedn=26

News(3)

  • Crystalys nets $130M more to push gout drug through late-stage tests
    The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in t…
    biopharma_dive · 20d ago
  • Crystalys mines $130M series B to push gout drug through phase 3
    Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch.
    fiercebiotech · 21d ago
  • Fierce Biotech Fundraising Tracker '26: Vaderis nets $152M series B; Epicrispr adds $90M
    The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
    fiercebiotech · 7mo ago
generic
dotinurad [INN]
indication
Gouty Arthritis (Gout)
phase
phase_3
Data sources
ClinicalTrials.gov
last refreshed 27m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?